COMxEP方案治疗非霍奇金淋巴瘤疗效观察

目的: 评价COMxEP联合化疗方案(VP₁₆、MxT、VCR、CTX、Pred)治疗非霍奇金淋巴瘤(non-Hodgkin'slympoma,NHL)的疗效和毒性。方法: 37例采用鬼臼乙叉苷(VP₁₆)60~70mg/m2,静脉滴注,第1~5天;米托蒽醌(MxT)6~8mg/m2,静脉滴注,第1天;长春新碱(VCR)1.4mg/m2,静脉推注,第1、8天;环磷酰胺(CTX)600~800mg,静脉推注,第1、8天;Pred每天40~60mg,口服,第l~5天。每4周为1疗程,均用4疗程以上,平均每例用4.8疗程。结果: CR率为67.6%,PR率为21.6%,SD率为14.3%,无PD,总缓解率为89.2%,中位缓解期为26个月;13例NHL复治患者,CR率为53.8%,PR率为30.8%,SD率为15.4%,无PD,总缓解率为84.6%。主要毒副反应为骨髓抑制、消化道反应和脱发。结论: COMxEP联合化疗方案治疗NHL初治或复发患者均有较高的缓解率,毒副反应较轻,可作为治疗NHL较理想的一线或二线化疗方案。

Effect of COMxEP regimens in treating non-Hodgkin's lymphoma

Objective:To evaluate the therapeutic effect and toxicity of COMxEP regimens in treatment of non-Hodgkin's lymphoma(NHL).Methods:Thirty-seven patients with intermediate-high grade NHL were treated with a combination chemotherapy of COMxEP.COMxEP regimen consisted of VP_(16),60-70 mg/m~2(iv gtt,Day1-5);MxT,6-8 mg/m~2(iv gtt,Day1);VCR,1.4 mg/m~2(iv,Day1,8);CTX,600-800 mg(iv,Day1,8);Pred,40-60 mg/day(po,Day1-5).One course lasted for 4 weeks and each patient received(4.8) courses on the average.Results:In the thirty seven patients receiving COMxEP regimen,complete remission(CR) rate was(67.6%),partial remission(PR) rate 21.6%,SD rate 14.3% and PD was no,and the overall response rate was 89.2%(33/37),with a median duration of 26 months.In the patients with refractory disease,CR rate was 53.8%,PR rate 30.8%,SD rate 15.4% and PD was no,and the overall response rate was 84.6%.The main side effects were bone marrow depression,enteron reaction and alopecie.Conclusions:COMxEP regimen is effective for patients with newly diagnosed or refractory disease,and the toxicity is tolerable.This regimen can be considered as a routine or salvage therapy for intermediate-high grade NHL.